Dividend Distribution - The company plans to distribute a cash dividend of 3 RMB per 10 shares to all shareholders, based on a total of 855,142,270 shares[4]. - The board of directors has approved the profit distribution plan, which includes no bonus shares and no capital increase from reserves[4]. - The company plans to distribute a cash dividend of 5.68 RMB per 10 shares for the 2023 fiscal year, totaling approximately 491.29 million RMB (including tax) based on a share base of 864,948,570 shares after accounting for repurchased shares[172]. - The total cash dividend amount, including repurchased shares, for the 2024 fiscal year is projected to be 447.69 million RMB, which represents 100% of the distributable profit of approximately 8.69 billion RMB[174]. - The company has not proposed any stock bonus shares for the 2023 fiscal year, maintaining a cash-only dividend policy[173]. - The cash dividend distribution plan complies with the company's articles of association and has been approved by the shareholders' meeting[173]. - The company has completed the implementation of the 2023 dividend distribution plan by the end of the reporting period[172]. - The company has not made any adjustments to its cash dividend policy during the reporting period, ensuring transparency and compliance with regulations[174]. Financial Performance - Tigermed reported a significant increase in revenue, achieving a total of 1.2 billion RMB, representing a year-over-year growth of 25%[19]. - The company's operating revenue for 2024 was ¥6,603,120,162.78, a decrease of 10.58% compared to ¥7,384,039,460.88 in 2023[23]. - The net profit attributable to shareholders for 2024 was ¥405,143,491.82, down 79.99% from ¥2,024,849,989.11 in 2023[23]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥854,895,425.22, a decrease of 42.13% from ¥1,477,242,053.32 in 2023[23]. - The basic earnings per share for 2024 was ¥0.47, down 79.91% from ¥2.34 in 2023[23]. - The total assets at the end of 2024 were ¥28,671,015,787.16, a decrease of 3.40% from ¥29,680,742,349.17 at the end of 2023[23]. - The company achieved a net new contract amount of RMB 8.42 billion in 2024, representing a year-on-year growth of 7.3%, with total pending contracts amounting to RMB 15.78 billion, up 12.1%[54]. - The company’s main business revenue for the reporting period was 647,408.51 million yuan, a decrease of 11.18% compared to the same period last year[71]. - Clinical trial technical service revenue was 317,813.99 million yuan, down 23.75% year-on-year, primarily due to a decline in domestic innovative drug clinical operations[71]. - The gross profit for the main business was CNY 2,153.78 million, a decrease of 22.62% compared to the previous year, with a gross profit margin dropping from 38.18% to 33.27%[82]. - The clinical trial technology service segment reported a gross profit of CNY 939.51 million, down 41.00% year-on-year, with a gross profit margin declining from 38.21% to 29.56%[83]. Strategic Direction and Market Expansion - The annual report outlines the company's strategic direction, including potential market expansions and new product developments[4]. - Tigermed anticipates continued growth, projecting a revenue increase of 20% for the next fiscal year, targeting 1.44 billion RMB[19]. - The company is focused on expanding its clinical research capabilities and enhancing its service offerings in the pharmaceutical sector[13]. - Tigermed is pursuing market expansion strategies, with plans to enter three new international markets by the end of the next fiscal year[19]. - The company is considering strategic acquisitions to bolster its market position, with a budget of $200 million allocated for potential targets[148]. - The company is actively investing in early-stage biopharmaceutical and medical device startups, leveraging its industry reputation and expertise to identify investment opportunities[44]. Operational Efficiency and Cost Management - Tigermed's operational efficiency improved, with a reduction in operational costs by 5%, leading to a higher profit margin of 18%[19]. - The company reported a 10% reduction in operational costs due to efficiency improvements implemented in the last quarter[150]. - The total operating cost was ¥4,320,302,084.19, with a year-on-year decrease of 4.12%[90]. Research and Development - The company is investing heavily in R&D, allocating 10% of its revenue, approximately 120 million RMB, towards new product development and technological advancements[19]. - The number of R&D personnel increased by 11.99% to 1,046 in 2024 from 934 in 2023[101]. - R&D expenditure as a percentage of operating revenue rose to 3.61% in 2024 from 3.54% in 2023[102]. - The company is developing an AI-based document automation processing system to enhance the efficiency and accuracy of clinical trial document handling[69]. - The company aims to enhance AI capabilities and expand application scenarios while ensuring high compliance standards[70]. Compliance and Governance - The company emphasizes the importance of accurate financial reporting and has ensured that all board members attended the meeting to review the annual report[4]. - The company maintains a robust governance structure, ensuring accountability and transparency in its operations[4]. - The company has established a quality management system that integrates digital, intelligent, and remote methods, aiming to enhance clinical operational efficiency and quality management capabilities[43]. - The company has a robust internal control system in place to manage risks effectively and ensure compliance with regulatory requirements[178]. - The company did not identify any significant internal control deficiencies during the reporting period[179]. Risks and Challenges - The company faces risks from potential natural disasters, pandemics, and other emergencies that could adversely affect its operations and financial performance[122]. - Demand for biopharmaceutical research services may decline if the global pharmaceutical market growth slows or if clients reduce their R&D budgets[123]. - The company is exposed to intensified competition in the global clinical contract research organization (CRO) market, which could pressure pricing and impact revenue[124]. - Future business expansion may fail if the company cannot effectively manage growth or implement its strategic initiatives[124]. - The company must maintain various regulatory approvals and licenses; failure to do so could severely impact its operations and financial health[125]. Employee and Talent Management - The total number of employees at the end of the reporting period is 10,185, with 1,770 in the parent company and 8,415 in major subsidiaries[167]. - The professional composition includes 8,982 technical personnel, 354 sales personnel, and 164 financial personnel[167]. - The company aims to build a diverse talent pool to meet future development needs, focusing on internal talent mobility and employee training[170]. - The global talent value proposition emphasizes inspiring potential and providing comprehensive career growth opportunities[171]. Shareholder Engagement and Communication - The company emphasizes investor communication and has established multiple channels for interaction, including performance briefings and an investor relations platform on its website[133]. - The company held its first temporary shareholders' meeting on March 21, 2024, with an investor participation rate of 44.01%[143]. - The annual shareholders' meeting on May 24, 2024, recorded a participation rate of 46.67%[143]. Acquisitions and Partnerships - The company has completed two strategic acquisitions in the past year, enhancing its service offerings and market reach[19]. - The company acquired Japan's CRO Medical Edge Co., Ltd. in July 2024, strengthening its data management and clinical data services in Japan and the Asia-Pacific region[58]. - The company acquired a 72.82% stake in Shanghai Guanho Pharmaceutical Technology Co., Ltd. during the reporting period[95]. - The company has established partnerships with five leading pharmaceutical firms to enhance its clinical trial services[19].

证券代码：300347 证券简称：泰格医药 公告编码（2025）016 号 杭州泰格医药科技股份有限公司 关于聘请会计师事务所的公告 公司及董事会全体成员保证公告内容的真实、准确和完整，对公告的虚假记载、误导性陈述或者 重大遗漏负连带责任。 杭州泰格医药科技股份有限公司（以下称"公司"）于2025年3月27日召开第五届董事会 第十四次会议和第五届监事会第九次会议，审议通过了《关于聘请公司2025年度审计机构 的议案》，拟继续聘请立信会计师事务所（特殊普通合伙）（以下简称"立信"）为公司2025 年度审计机构。现将相关情况公告如下： 一、拟聘任会计师事务所事项的情况说明 立信会计师事务所（特殊普通合伙）经财政部和中国证监会批准具有证券业从业资格， 并有资格向在香港上市的内地注册成立的发行人提供使用内地审计准则的审计服务。公司 签字注册会计师和项目负责人具有相应的专业胜任能力，在执业过程中坚持以独立、客观、 公正的态度进行审计，表现了良好的职业规范和精神，公司董事会拟继续聘请立信会计师 事务所（特殊普通合伙）为公司2025年度审计机构。 二、拟聘任会计师事务所基本情况说明 （一）机构信息 1、基本信息 立信会计师 ...

3月27日，泰格医药今日收盘55.39元，上涨4.31%，滚动市盈率PE（当前股价与前四季度每股收益总和 的比值）达到49.97倍，总市值479.10亿元。 序号股票简称PE(TTM)PE(静)市净率总市值(元)31泰格医药49.9723.662.27479.10亿行业平均 44.4436.563.80166.76亿行业中值43.6934.112.8451.38亿1昭衍新药-18045.8841.502.06164.74亿2普瑞眼 科-185.6823.212.8062.18亿3何氏眼科-163.8450.231.6531.92亿4迪安诊断-108.4432.651.42100.37亿5光正眼 科-96.91230.247.8121.31亿6南华生物-88.23-116.0913.1532.71亿7创新医疗-86.66-121.112.2541.52亿8国际 医学-35.91-34.923.52128.62亿9嘉和美康-29.90-29.902.5144.84亿10皓宸医疗-24.98-25.735.4224.28亿11美 迪西-14.06-14.061.8944.42亿 从行业市盈率排名来看，公司所处的医疗 ...

泰格医药收盘下跌1.80%，滚动市盈率48.64倍，总 市值466.29亿元 3月24日，泰格医药今日收盘53.91元，下跌1.80%，滚动市盈率PE（当前股价与前四季度每股收益总和 的比值）达到48.64倍，总市值466.29亿元。 从行业市盈率排名来看，公司所处的医疗服务行业市盈率平均44.02倍，行业中值43.09倍，泰格医药排 名第31位。 杭州泰格医药科技股份有限公司专注于为新药研发提供临床试验全过程专业服务的合同研究组织 (CRO)，为全球医药和医疗器械创新企业提供全面而综合的临床研究解决方案。主要产品为临床试验技 术服务、临床试验相关服务及实验室服务等。公司是中国领先的综合生物制药研发服务提供商,且全球 的影响力正在不断扩大。 最新一期业绩显示，2024年三季报，公司实现营业收入50.68亿元，同比-10.32%；净利润8.13亿元，同 比-56.72%，销售毛利率38.88%。 序号股票简称PE(TTM)PE(静)市净率总市值(元)31泰格医药48.6423.032.21466.29亿行业平均 44.0236.433.77165.13亿行业中值43.0933.112.8549.18亿1昭衍新药 ...

泰格医药业绩暴跌：CRO行业泡沫破裂的警示？ 作为中国CRO（合同研究组织）行业的领军企业， 泰格医药 （300347.SZ）在2024年的财务表现令市场 震惊。公司预计全年营收下滑，归母净利润暴跌72%-81%，创下上市以来的最大跌幅。利润大幅缩水的 背后，折射出CRO行业正面临深刻变局，甚至可能进入寒冬期。 2024年上半年，泰格医药主营业务收入32.96亿元，同比下降10.21%。其中，占比最大的临床试验 技术 服务 （CTS）收入同比下降22.17%，仅16.37亿元，毛利率从39.7%下滑至38.4%。尽管实验室服务 （CRLS）相对稳定，但整体盈利能力已明显承压。这种趋势表明，泰格医药所处的CRO行业正在经历 激烈的价格战，而企业的盈利模式正受到挑战。 CRO行业陷入"零和博弈"，价格战压垮利润 泰格医药的困境并非个例，而是整个行业的缩影。2023年下半年以来，国内临床运营市场的竞争加剧， 订单价格普遍下滑，使得CRO企业在争取市场份额的同时，被迫压低价格，盈利能力严重受损。这 种"零和博弈"模式导致全行业利润被摊薄，而泰格医药作为行业代表，其毛利率的下降正是这一趋势的 象征。 投资收益成"双刃剑 ...

董事會會議召開日期 杭 州 泰 格 醫 藥 科 技 股 份 有 限 公 司（「本公司」）董 事（「董 事」）會（「董事會」）謹 此 宣 佈，董 事 會 會 議 將 於 二 零 二 五 年 三 月 二 十 七 日（星 期 四）舉 行，藉 以（其 中 包 括）審 議 及 批 准 本 公 司 及 其 附 屬 公 司 截 至 二 零 二 四 年 十 二 月 三 十 一 日 止 年 度 的 全 年 業 績 及 其 刊 發，以 及 考 慮 建 議 派 發 末 期 股 息（如 適 用）。 承董事會命 杭州泰格醫藥科技股份有限公司 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內 容 概 不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不對因本公告全部或任何部分內容而產生或因依賴該等內容而引致的 任 何 損 失 承 擔 任 何 責 任。 HANGZHOU TIGERMED CONSULTING CO., LTD. 杭州泰格醫藥科技股份有限公司 （於 中 華 人 民 共 和 國 註 冊 成 立 的 股 份 有 限 公 司） （股 份 代 號：3347） 香 港 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內 容 概 不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不對因本公告全部或任何部分內容而產生或因依賴該等內容而引致的 任 何 損 失 承 擔 任 何 責 任。 杭 州 泰 格 醫 藥 科 技 股 份 有 限 公 司（「本公司」）董 事（「董 事」）會（「董事會」）謹 此 宣 佈，董 事 會 會 議 將 於 二 零 二 五 年 三 月 二 十 七 日（星 期 四）舉 行，藉 以（其 中 包 括）審 議 及 批 准 本 公 司 及 其 附 屬 公 司 截 至 二 零 二 四 年 十 二 月 三 十 一 日 止 年 度 的 全 年 業 績 及 其 刊 發，以 及 考 慮 建 議 派 發 末 期 股 息（如 適 用）。 承董事會命 杭州泰格醫藥科技股份有限公司 董事長 HANGZHOU TIGERMED CONSULTING CO., LTD. 杭州泰格醫藥科技股份有限公司 （於 中 華 人 民 共 和 國 註 冊 成 立 的 股 份 有 限 公 司） （股 份 代 號：3347） 董事會會議召開日期 ...

Group 1 - The establishment of Tiger Med (Shenzhen) Pharmaceutical Technology Co., Ltd. has been reported, with a registered capital of 1 million yuan [1] - The legal representative of the new company is Shan Bin, and its business scope includes medical research and experimental development, translation services, conference and exhibition services, market research (excluding foreign-related investigations), technology import and export, and data processing services [1] - Tiger Med holds indirect full ownership of the newly established company [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內 容 概 不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不對因本公告全部或任何部分內容而產生或因倚賴該等內容而引致的 任 何 損 失 承 擔 任 何 責 任。 HANGZHOU TIGERMED CONSULTING CO., LTD. 杭州泰格醫藥科技股份有限公司 （於 中 華 人 民 共 和 國 註 冊 成 立 的 股 份 有 限 公 司） （股 份 代 號：3347） 海外監管公告 本 公 告 乃 杭 州 泰 格 醫 藥 科 技 股 份 有 限 公 司（「本公司」）根 據 香 港 聯 合 交 易 所有限公司證券上市規則第13.10B條 而 作 出。 茲 載 列 本 公 司 於 深 圳 證 券 交 易 所 網 站 刊 登 公 告 如 下，僅 供 參 閱。 承董事會命 杭州泰格醫藥科技股份有限公司 董事長 葉小平 香 港，2025年3月4日 於 本 公 告 日 期，執 行 董 事 為 葉 小 平 博 士、曹 曉 春 女 士、吳 灝 先 生 及 聞增玉先生；獨立非執行董事為廖啟宇先生、袁華剛先 ...

| 1. 股份分類 | 普通股 | 股份類別 | A | | | 於香港聯交所上市 (註1) | 否 | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 300347 | 說明 | | 於深圳證券交易所上市 | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 741,823,770 | RMB | | 1 RMB | | | 741,823,770 | | 增加 / 減少 (-) | | | 0 | | | RMB | | | 0 | | 本月底結存 | | | 741,823,770 | RMB | | 1 RMB | | | 741,823,770 | | 2. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 0334 ...